Holen Sie sich die Stockscreener-App
3.58
0.56%
-0.02
Schlusskurs vom Vortag:
$3.60
Offen:
$3.59
24-Stunden-Volumen:
52,647
Relative Volume:
0.36
Marktkapitalisierung:
$135.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.66M
KGV:
-3.7684
EPS:
-0.95
Netto-Cashflow:
$-24.36M
1W Leistung:
+5.29%
1M Leistung:
+28.78%
6M Leistung:
-9.60%
1J Leistung:
+64.98%
1-Tages-Spanne:
$3.55
$3.70
1-Wochen-Bereich:
$3.26
$3.70
52-Wochen-Spanne:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Vergleichen Sie GNLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.58 | 124.61M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.84 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.27 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.03 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
581.51 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Genelux Corp Aktie (GNLX) Neueste Nachrichten
Genelux Corporation Stock Analysis and ForecastHigh-yield investments - Autocar Professional
What drives Genelux Corporation stock priceFree Buy/Sell Signal Notifications - Autocar Professional
Genelux stock maintains Buy rating at H.C. Wainwright amid sector news By Investing.com - Investing.com South Africa
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy - TipRanks
Lucid Capital Initiates Coverage on Genelux with a Buy Rating, Setting a Price Target of $10. - AInvest
Lucid Capital Initiates Coverage of Genelux with Buy Rating and $10 Price Target - AInvest
What analysts say about Genelux Corporation stockFree Stock Selection - Autocar Professional
Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target By Investing.com - Investing.com South Africa
Genelux initiated with a Buy at Lucid Capital - TipRanks
Is Genelux Corporation a good long term investmentExceptional portfolio growth - Autocar Professional
Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead - TipRanks
What risks could impact Genelux Corporation stock performanceExpert Trading Flow - Newser
Genelux Corporation (NASDAQ:GNLX) Position Trimmed by Stratos Wealth Partners LTD. - Defense World
Why Genelux Corporation stock attracts strong analyst attentionProven Win Setups - Newser
What makes Genelux Corporation stock price move sharplyFree VIP Investment Strategies - Newser
Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen - Defense World
Amgen Alum Takes Legal Reins of Biotech Firm Developing Cancer Treatment - Law.com
Genelux Appoints Groen as General Counsel From Rani Therapeutics - Bloomberg Law News
Biopharma Co. Genelux Hires Life Sciences Veteran As GC - Law360
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO - TipRanks
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development - MarketScreener
Former Amgen $10B Deal Architect Joins Genelux Leadership to Drive Strategic Growth - Stock Titan
Genelux Corporation Appoints Eric Groen as General Counsel and Head of Business Development - Quiver Quantitative
Genelux Corporation (NASDAQ:GNLX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
June 2025's Promising Penny Stocks For Savvy Investors - simplywall.st
Two Sigma Investments LP Sells 18,446 Shares of Genelux Co. (NASDAQ:GNLX) - Defense World
Citadel Advisors LLC Lowers Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Millennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Squarepoint Ops LLC - Defense World
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - Defense World
Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Genelux (NASDAQ:GNLX) Trading Up 3.3% – Time to Buy? - Defense World
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Top Executives at Genelux Corp. Unload Thousands of Shares! - TipRanks
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView
Genelux Q3 EPS Raised by Brookline Capital Management - Defense World
HC Wainwright Issues Optimistic Outlook for Genelux Earnings - Defense World
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position - TipRanks
Genelux (GNLX) Price Target Lowered by Benchmark Analyst | GNLX Stock News - GuruFocus
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating - TipRanks
H.C. Wainwright lifts Genelux stock target to $31, maintains buy By Investing.com - Investing.com Nigeria
H.C. Wainwright lifts Genelux stock target to $31, maintains buy - Investing.com
Genelux reports Q1 EPS (21c), consensus (24c) - TipRanks
Genelux (GNLX) Shows Strong Progress in Cancer Treatment Trials | GNLX Stock News - GuruFocus
Genelux Reports 71% Disease Control Rate in Lung Cancer Trial, Q1 2025 Earnings | GNLX Stock News - Stock Titan
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates - Yahoo Finance
Geode Capital Management LLC Has $716,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux CEO Discusses Next-Gen Immuno-Oncology Pipeline and Key Milestones at Citizens Conference - Stock Titan
LPL Financial LLC Has $222,000 Stock Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Raymond James Financial Inc. Takes $41,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.89%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):